| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Juhani Knuuti | Q11867479 |
| P2093 | author name string | J J Bax | |
| D Le Guludec | |||
| F M Bengel | |||
| European Council of Nuclear Cardiology | |||
| R Lautamäki | |||
| P2860 | cites work | PET myocardial glucose metabolism and perfusion imaging: Part 1-Guidelines for data acquisition and patient preparation | Q30882564 |
| Monitoring of bone marrow cell homing into the infarcted human myocardium | Q31162853 | ||
| Quantification of myocardial perfusion in human subjects using 82Rb and wavelet-based noise reduction | Q32053874 | ||
| Detection of coronary artery stenoses with thin-slice multi-detector row spiral computed tomography and multiplanar reconstruction | Q33186018 | ||
| Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. | Q34132798 | ||
| ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 G | Q34230607 | ||
| Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. | Q34492497 | ||
| The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction | Q34794169 | ||
| Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. | Q35366928 | ||
| Why do plaques rupture? | Q35478515 | ||
| Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. | Q35943581 | ||
| Molecular and metabolic imaging of atherosclerosis. | Q35943591 | ||
| Noninvasive assessment of coronary collaterals in man by PET perfusion imaging | Q68717753 | ||
| Reversibility of cardiac wall-motion abnormalities predicted by positron tomography | Q68794490 | ||
| Economic analysis of clinical positron emission tomography of the heart with rubidium-82 | Q69738342 | ||
| Diffuse slow washout of myocardial thallium-201: a new scintigraphic indicator of extensive coronary artery disease | Q71395206 | ||
| Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium | Q71664790 | ||
| Evaluation of patterns of perfusion and metabolism in dobutamine-responsive myocardium | Q71975668 | ||
| Detection of coronary collaterals using dipyridamole PET myocardial perfusion imaging with rubidium-82 | Q71980419 | ||
| Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography | Q71998777 | ||
| Relation between regional myocardial uptake of rubidium-82 and perfusion: absolute reduction of cation uptake in ischemia | Q72110130 | ||
| Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: comparison with fluorine-18-FDG PET | Q72348319 | ||
| Identification of hibernating myocardium: a comparison between dobutamine echocardiography and study of perfusion and metabolism in patients with severe left ventricular dysfunction | Q72639678 | ||
| Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis | Q72729798 | ||
| Hibernating myocardium versus scar: severity of irreversible decreased myocardial perfusion in prediction of tissue viability | Q72899804 | ||
| Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols | Q73099192 | ||
| The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction | Q73191075 | ||
| F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function | Q73256698 | ||
| No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocard | Q73386965 | ||
| Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability | Q74611618 | ||
| Quantitative evaluation of a comprehensive motion, resolution, and attenuation correction program: initial experience | Q77492657 | ||
| Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging | Q77681067 | ||
| Comparative performance of gated perfusion SPECT wall thickening, delayed thallium uptake, and F-18 fluorodeoxyglucose SPECT in detecting myocardial viability | Q78169454 | ||
| Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis | Q79174837 | ||
| In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients | Q79328884 | ||
| Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: a 82Rb PET/CT study | Q79856924 | ||
| Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium | Q80044884 | ||
| Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium: comparison with 99mTc-tetrofosmin | Q80341053 | ||
| Occupational radiation dose associated with Rb-82 myocardial perfusion positron emission tomography imaging | Q83916388 | ||
| Myocardial blood flow measurement by PET: technical aspects and clinical applications | Q35999659 | ||
| Cardiac positron emission tomography imaging | Q36006708 | ||
| Cardiovascular MR to access myocardial viability in chronic ischaemic LV dysfunction | Q36257372 | ||
| Atherosclerosis imaging on the molecular level | Q36390068 | ||
| Radionuclide imaging for the detection of inflammation in vulnerable plaques | Q36456547 | ||
| Nuclear imaging in cardiac cell therapy | Q36666478 | ||
| New technology for noninvasive evaluation of coronary artery disease | Q36764400 | ||
| Hibernating myocardium: diagnosis and patient outcomes | Q36846289 | ||
| Radiation dose to patients from cardiac diagnostic imaging | Q36936679 | ||
| Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: a position statement | Q37059545 | ||
| Combined imaging of molecular function and morphology with PET/CT and SPECT/CT: image fusion and motion correction | Q37103735 | ||
| PET versus SPECT: strengths, limitations and challenges | Q37113397 | ||
| Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study | Q37638667 | ||
| Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction | Q38528062 | ||
| Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease. | Q39097731 | ||
| Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography | Q39773232 | ||
| Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated (82)rubidium myocardial perfusion PET. | Q40167809 | ||
| The regulatory background of nuclear cardiology in Europe: a survey by the European Council of Nuclear Cardiology | Q40297877 | ||
| Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. | Q40373416 | ||
| Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events | Q40426548 | ||
| Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. | Q40562002 | ||
| Coronary flow reserve is reduced in young men with IDDM. | Q40865342 | ||
| Diagnosis of coronary artery disease in women: roles of three dimensional imaging with magnetic resonance or positron emission tomography | Q41015281 | ||
| Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease | Q41650517 | ||
| Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity | Q42540823 | ||
| Coronary flow reserve is impaired in young men with familial hypercholesterolemia | Q42551881 | ||
| Quantification of regional myocardial blood flow in vivo with H215O | Q42665804 | ||
| Myocardial perfusion with rubidium-82. II. Effects of metabolic and pharmacologic interventions | Q42667588 | ||
| Cine CT for attenuation correction in cardiac PET/CT. | Q43241087 | ||
| Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans | Q43561986 | ||
| Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography | Q43854296 | ||
| Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction | Q43854302 | ||
| Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. | Q44304953 | ||
| Myocardial perfusion and viability by positron emission tomography in infants and children with coronary abnormalities: correlation with echocardiography, coronary angiography, and histopathology. | Q44323031 | ||
| False-negative myocardial scintigraphy in balanced three-vessel disease, revealed by coronary pressure measurement | Q44440224 | ||
| Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy | Q44580888 | ||
| The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis | Q44733480 | ||
| Stress myocardial perfusion single-photon emission computed tomography is clinically effective and cost effective in risk stratification of patients with a high likelihood of coronary artery disease (CAD) but no known CAD. | Q44736945 | ||
| (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study | Q44964637 | ||
| Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease | Q45007821 | ||
| Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis | Q45178281 | ||
| Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography | Q45231282 | ||
| Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis | Q46421278 | ||
| Quantitative dynamic cardiac 82Rb PET using generalized factor and compartment analyses. | Q46639225 | ||
| Initial characterization of an 18F-labeled myocardial perfusion tracer | Q46698781 | ||
| Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction | Q46877910 | ||
| Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent | Q46894197 | ||
| F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). | Q46904667 | ||
| Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease | Q46917095 | ||
| CT-based attenuation correction in (82)Rb-myocardial perfusion PET-CT: incidence of misalignment and effect on regional tracer distribution | Q46971566 | ||
| Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease | Q46973566 | ||
| Dual cardiac-respiratory gated PET: implementation and results from a feasibility study. | Q48596641 | ||
| (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. | Q48904408 | ||
| Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects. | Q50533784 | ||
| What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? | Q50788281 | ||
| Integrated single-photon emission computed tomography and computed tomography coronary angiography for the assessment of hemodynamically significant coronary artery lesions. | Q51052038 | ||
| Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. | Q51595033 | ||
| Comparative myocardial uptake of intravenously administered radionuclides. | Q51674877 | ||
| Cardiac 82Rubidium PET/CT: initial European experience. | Q51739442 | ||
| Comparison of 2-dimensional and 3-dimensional 82Rb myocardial perfusion PET imaging. | Q51839676 | ||
| Artifacts from misaligned CT in cardiac perfusion PET/CT studies: frequency, effects, and potential solutions. | Q51924119 | ||
| Estimation of myocardial blood flow and myocardial flow reserve by 99mTc-sestamibi imaging: comparison with the results of [15O]H2O PET. | Q52023674 | ||
| Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. | Q52295897 | ||
| Comparison of cost-effectiveness and utility of exercise ECG, single photon emission computed tomography, positron emission tomography, and coronary angiography for diagnosis of coronary artery disease. | Q52358959 | ||
| Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. | Q53018896 | ||
| Relationship between CT coronary angiography and stress perfusion imaging in patients with suspected ischemic heart disease assessed by integrated PET-CT imaging. | Q53452706 | ||
| BMS-747158-02: a novel PET myocardial perfusion imaging agent. | Q53452708 | ||
| Impact of myocardial perfusion imaging with PET and (82)Rb on downstream invasive procedure utilization, costs, and outcomes in coronary disease management. | Q53474605 | ||
| Frequent diagnostic errors in cardiac PET/CT due to misregistration of CT attenuation and emission PET images: a definitive analysis of causes, consequences, and corrections. | Q53476732 | ||
| Relationship between noninvasive coronary angiography with multi-slice computed tomography and myocardial perfusion imaging. | Q53508054 | ||
| Noninvasive characterization of myocardial molecular interventions by integrated positron emission tomography and computed tomography. | Q53511839 | ||
| Comparison of spiral multidetector CT angiography and myocardial perfusion imaging in the noninvasive detection of functionally relevant coronary artery lesions: first clinical experiences. | Q53574701 | ||
| Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound. | Q53579424 | ||
| Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. | Q54301756 | ||
| Cardiac computed tomography: indications, applications, limitations, and training requirements: Report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council o | Q57623003 | ||
| EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology | Q57623069 | ||
| Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography | Q57623385 | ||
| EANM/ESC guidelines for radionuclide imaging of cardiac function | Q57682319 | ||
| Effect of aging on myocardial perfusion reserve | Q61651531 | ||
| Issues regarding radiation dosage of cardiac nuclear and radiography procedures | Q66829618 | ||
| Prediction of reversible ischemia after coronary artery bypass grafting by positron emission tomography | Q67908880 | ||
| Balanced triple-vessel disease: enhanced detection by estimated myocardial thallium uptake | Q68087000 | ||
| Value and limitation of stress thallium-201 single photon emission computed tomography: comparison with nitrogen-13 ammonia positron tomography | Q68095624 | ||
| Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose | Q68177130 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P1104 | number of pages | 16 | |
| P304 | page(s) | 1709-1724 | |
| P577 | publication date | 2008-06-26 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Present and future of clinical cardiovascular PET imaging in Europe--a position statement by the European Council of Nuclear Cardiology (ECNC). | |
| P478 | volume | 35 |
| Q91647569 | Automated concentration of [18F]fluoride into microliter volumes |
| Q33688206 | Cardiac PET-CT: advanced hybrid imaging for the detection of coronary artery disease. |
| Q38723494 | Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). |
| Q35583402 | Coronary risk factors and myocardial blood flow in patients evaluated for coronary artery disease: a quantitative [15O]H2O PET/CT study |
| Q47286597 | Evaluating the prognostic value of positron-emission tomography myocardial perfusion imaging using automated software to calculate perfusion defect size. |
| Q44052628 | First experience of combined cardiac PET/64-detector CT angiography with invasive angiographic validation |
| Q57622472 | Hybrid cardiac imaging: SPECT/CT and PET/CT. A joint position statement by the European Association of Nuclear Medicine (EANM), the European Society of Cardiac Radiology (ESCR) and the European Council of Nuclear Cardiology (ECNC) |
| Q33781237 | Impact of preoperative positron emission tomography in patients with severely impaired LV-function undergoing surgical revascularization |
| Q34260475 | Molecular imaging of plaques in coronary arteries with PET and SPECT. |
| Q36325479 | Myocardial perfusion scintigraphy: past, present and future |
| Q37288099 | Quantitative cardiac positron emission tomography: the time is coming! |
| Q38737734 | Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography. |
| Q38993426 | Synthesis and bioevaluation of 4-chloro-2-tert-butyl-5-[2-[[1-[2-[(18) F]fluroethyl]-1H-1,2,3-triazol-4-yl]methyl]phenylmethoxy]-3(2H)-pyridazinone as potential myocardial perfusion imaging agent with PET. |
| Q57988200 | Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathy |
| Q37868709 | Vascular imaging with positron emission tomography. |
Search more.